Eye-gaze feedback task for attention training in major depressive disorder
Tests a gaze-based attention task using sound feedback in adults with depression.
Key facts
- Who runs it
- Tel Aviv University
- Where
- Tel Aviv, IsraelSee the site
- Trial code
- Registry title
- Gaze Contingent Attentional Reinforcement in Major Depressive Disorder
- Status
- Not yet recruiting
- People taking part
- 60 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 1 Jan 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Aversive white noise
- Music reward
- Record updated
- 23 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with major depressive disorder as their main diagnosis. It tests a gaze-based attention training task.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Primary diagnosis of major depressive disorder (MDD), with a MADRS score of 7 or higher.
- Earlier treatment
- If taking medicine, the dose must have been stable for at least three months. People in other psychotherapy at the same time cannot join. People who had ECT (electroconvulsive therapy) recently cannot join.
- Biomarker or test result
- Normal vision, or vision corrected to normal. Eye-tracking must be possible.
Main reasons for not taking part
- Past or present psychosis, manic or hypomanic episode, or PTSD
- High suicidal thoughts or behavior
- Severe alcohol or cannabis use disorder, or any other substance use disorder (except nicotine)
- Unstable or untreated medical illness
- Organic mental disorder, seizure or brain injury, now or in the past
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Primary diagnosis of MDD
- MADRS>=7
- Normal or corrected-t-normal vision
Who cannot take part
- Pharmacological treatment if not stabilized for at least three months or concurrent psychotherapy
- Severe alcohol or cannabis use disorder, and/or any severity of other substance use disorder (exepct nicotine use)
- Current unstable or untreated medical illness
- Current or past organic mental disorder, seizure or brain injury
- Present or past psychosis, manic or hypomanic episode, PTSD
- High suicidal ideation or behavior
- Eye-tracking calibration difficulties
- Post-ECT treatment
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in Israel
- Tel Aviv UniversityTel Aviv, IsraelContact: Shani Lavi, M.A.No longer taking part
About the trial
What the trial wants to find out
The main objective of this randomized controlled trial is to evaluate whether a gaze-contingent feedback task using negative reinforcement can serve as an effective attention-modification procedure and contribute to the treatment of Major Depressive Disorder (MDD).
The 2 groups in the trial
- Gaze contingent negative reinforcementExisting treatment, for comparison
participants will receive gaze-contingent negative reinforcement according to their viewing patterns
Treatment: Aversive white noise
- Gaze contingent positive reinforcementPlacebo, for comparison
participants will receive gaze-contingent positive reinforcement according to their viewing patterns
Treatment: Music reward
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Gaze Contingent Attentional Reinforcement Treatment of MDD
- Plain-language title
- Eye-gaze feedback task for attention training in major depressive disorderGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07364981, who can take part
- Record updated
- 23 January 2026